AngioDynamics Q1 Beats on Med Tech Growth, Reiterates FY27 Guidance
ANGO sits 50% above its 52-week low of $9.39 on elevated volume (2.0× avg).
Summary
AngioDynamics reported fiscal Q1 sales of $80.9M, up 6.9% and slightly above the $80.5M consensus. Adjusted loss per share of $0.04 beat the $0.11 expected, and adjusted net loss of $1.8M was far better than the $4.81M estimate. Med Tech drove the beat with double-digit growth, led by Auryon, Mechanical Thrombectomy, and NanoKnife, which rose 29% on prostate procedure demand. Gross margin improved on pricing, mix shift, and tariff refunds. Management reiterated FY2027 sales guidance of $336M-$341M and adjusted EPS of ($0.29)-($0.24). This follows the July 14 10-K showing FY2026 revenue of $320.2M and the October 8 CEO transition announcement.
At the time of this announcement, ANGO was trading at $14.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $596.8M. The 52-week trading range was $9.39 to $16.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.